Kliničke studije za Гојазност u državi Тенеси
24 studija za Гојазност traži učesnike na lokacijama u državi Тенеси.
Gradovi u državi Тенеси
Zvanični tekst studije (na engleskom)
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07351045A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Franklin
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07776509A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
- Clinical Research Associates, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07843498A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- New Phase Research and Development, Knoxville
- Clinical Research Associates Inc, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07794579A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06857942Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937086A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
Тражи се учесникФаза 3
Узраст од 6 до 17 · Оба пола · Ажурирано 4. 11. 2026. · NCT06672549Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
- Alliance for Multispecialty Research - Knoxville, Knoxville
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 2. 11. 2026. · NCT07908316A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
- Research Site, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07784725A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07784270Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- и још 1
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07752979Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 26. 10. 2026. · NCT07837973A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
Тражи се учесникФаза 3Здраве особе су добродошле
Узраст од 18 до 79 · Оба пола · Ажурирано 20. 10. 2026. · NCT07654374Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07607587A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 8. 10. 2026. · NCT07589608A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 7. 10. 2026. · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
- Accellacare US Inc., d/b/a Accellacare of Knoxville, Knoxville
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 5. 10. 2026. · NCT07684235A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
Тражи се учесникФаза 3
Узраст од 8 до 18 · Оба пола · Ажурирано 30. 9. 2026. · NCT07253285A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT07321886A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743463Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
Тражи се учесникФаза 3
Узраст од 18 до 79 · Оба пола · Ажурирано 10. 8. 2026. · NCT07654361A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
Тражи се учесникФаза 1
Узраст од 18 до 65 · Оба пола · Ажурирано 9. 6. 2026. · NCT07142707Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.